Pathophysiology of L-dopa-induced motor and non-motor complications in Parkinson's disease. (September 2015)

• Record Type: Journal Article
• Authors: Bastide, Matthieu F.; Meissner, Wassilios G.; Picconi, Barbara; Fasano, Stefania; Fernagut, Pierre-Olivier; Feyder, Michael; Francardo, Veronica; Alcacer, Cristina; Ding, Yunmin; Brambilla, Riccardo; Fisone, Gilberto; Jon Stoessl, A.; Bourdenx, Mathieu; Engeln, Michel; Navailles, Sylvia; De Deurwaerdère, Philippe; Ko, Wai Kin D.; Simola, Nicola; Morelli, Micaela; Groc, Laurent; Rodriguez, Maria-Cruz; Gurevich, Eugenia V.; Quik, Maryka; Morari, Michele; Mellone, Manuela; Gardoni, Fabrizio; Tronci, Elisabetta; Guehl, Dominique; Tison, François; Crossman, Alan R.; Kang, Un Jung; Steece-Collier, Kathy; Fox, Susan; Carta, Manolo; Angela Cenci, M.; Bézard, Erwan;
• Is Part Of: Progress in neurobiology. Volume 132(2015:Sep.)
• Page Start: 96
• Page End: 168
• Publication Date: 2015-09
• Subjects: Parkinson's disease -- Dyskinesia -- L-dopa -- Dopamine -- Animal models -- D1 receptor; Neurobiology -- Periodicals; Neurology -- Periodicals; Neurology -- Periodicals; Neurobiologie -- Périodiques; 612.8
• DOI: 10.1016/j.pneurobio.2015.07.002
• Languages: English
• ISSNs: 0301-0082

Abstract

Highlights: Dyskinesia represents a debilitating complication of levodopa therapy for Parkinson's disease. There appeared a critical need to re-frame the concepts, to highlight the most suitable models, to review the central nervous system circuitry. To propose a pathophysiological framework was timely and necessary. This review thus provides an overview of our current understanding of dyskinesia. Abstract: Involuntary movements, or dyskinesia, represent a debilitating complication of levodopa (L-dopa) therapy for Parkinson's disease (PD). L-dopa-induced dyskinesia (LID) are ultimately experienced by the vast majority of patients. In addition, psychiatric conditions often manifested as compulsive behaviours, are emerging as a serious problem in the management of L-dopa therapy. The present review attempts to provide an overview of our current understanding of dyskinesia and other L-dopa-induced dysfunctions, a field that dramatically evolved in the past twenty years. In view of the extensive literature on LID, there appeared a critical need to re-frame the concepts, to highlight the most suitable models, to review the central nervous system (CNS) circuitry that may be involved, and to propose a pathophysiological framework was timely and necessary. An updated review to clarify our understanding of LID and other L-dopa-related side effects was therefore timely and necessary. This review should help in the development of novel therapeutic strategies aimed at preventing the generation of dyskinetic symptoms.